For example, androgen deprivation therapy (ADT), such as leuprolide and degarelix, and ARSIs, such as abiraterone and enzalutamide, have served us well for the treatment of the bulk of prostate non-CSCs that are dependent on AR signal pathways and can be detected in the tumor tissue and measured in the blood by the biomarker, prostatic specific antigen (PSA). Here, AR is linked to neoplasm.